Free Trial
NASDAQ:CYCC

Cyclacel Pharmaceuticals Q3 2024 Earnings Report

Cyclacel Pharmaceuticals logo
$0.26 +0.03 (+14.41%)
As of 10:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.54
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A

Cyclacel Pharmaceuticals Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.01 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Cyclacel Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
12:00AM ET

Upcoming Earnings

Cyclacel Pharmaceuticals' Q1 2025 earnings is scheduled for Wednesday, May 7, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cyclacel Pharmaceuticals Earnings Headlines

$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
See More Cyclacel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (NASDAQ:CYCC), a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

View Cyclacel Pharmaceuticals Profile

More Earnings Resources from MarketBeat